6 quiz questions available for this topicTake Quiz

Haematospermia

888 wordsUpdated 03/03/2026
💡

Exam Tips

  • In OSCEs, age stratification is high yield: isolated single episode in men <40 with normal exam/investigations is usually benign; unexplained haematospermia in men >40 needs urology referral.
  • Always ask red flags: persistent/recurrent episodes, haematuria, weight loss, bone pain, testicular mass, fever, STI symptoms, and recent instrumentation.
  • Core initial tests in primary care: urinalysis + MSU for all, PSA in men >40 (or suspicious history/exam at any age), and focused bloods if systemic cause suspected.
  • Do not miss referral triggers: suspected prostate/testicular/urological cancer or haematological malignancy should go via 2-week suspected cancer pathway.
  • Counselling point: fertility is usually unaffected, but untreated chlamydia/gonorrhoea can impair fertility and requires partner management.

Definition

Haematospermia is the presence of blood in ejaculate, either visibly red/brown semen or blood detected incidentally on semen analysis. It is usually benign and self-limiting, particularly in younger men, but recurrent/persistent episodes or presentation in men aged 40 years and over should prompt evaluation for significant underlying pathology including malignancy.

Pathophysiology

Bleeding usually arises from inflamed, infected, obstructed, or traumatised structures along the seminal pathway (prostate, seminal vesicles, ejaculatory ducts, urethra), with seminal vesicles a frequent source on modern imaging. Fresh bleeding gives bright red semen, while older blood appears brown due to haemoglobin breakdown; systemic contributors include severe hypertension, coagulopathy, liver disease, and anticoagulant exposure. Malignancy risk increases with age and with persistent/recurrent bleeding. See figure: prostate-seminal vesicle-ejaculatory duct anatomy in a standard urology/pelvic anatomy textbook.

Risk Factors

  • Age 40 years or older
  • Recent urological procedures (for example prostate biopsy, cystoscopy, vasectomy, radiotherapy)
  • Sexually transmitted infection risk (new/multiple partners, unprotected sex)
  • Urinary tract infection history
  • Prostatitis history
  • Pelvic/perineal/genital trauma or coital trauma
  • Anticoagulant or antiplatelet therapy
  • Severe uncontrolled hypertension
  • Personal/family bleeding disorder or easy bruising
  • Travel/residence in tuberculosis or schistosomiasis endemic regions
  • Family history of prostate cancer and Black ethnicity (higher baseline prostate cancer risk)

Clinical Features

Symptoms

  • Visible blood in semen (bright red, clots, or brown discolouration)
  • Single episode or recurrent episodes over weeks to months
  • Dysuria, frequency, urgency, suprapubic/perineal/pelvic pain (suggesting UTI/prostatitis)
  • Urethral discharge or genital lesions (suggesting STI)
  • Painless visible haematuria (red flag for urological malignancy)
  • LUTS (hesitancy, weak stream, dribbling) suggesting BPH/prostate pathology
  • Scrotal discomfort or unilateral testicular change/swelling

Signs

  • Fever in infective causes
  • Hypertension on examination
  • Urethral meatal discharge, lesions, or trauma
  • Epididymal/testicular tenderness, swelling, or mass
  • Abdominal mass/hepatosplenomegaly or lymphadenopathy (systemic disease clues)
  • DRE findings: tender boggy prostate (prostatitis) or hard/nodular/asymmetric prostate (possible cancer)
  • Petechiae/ecchymoses suggesting bleeding tendency

Investigations

Urinalysis (all patients):May show blood, leucocytes, or nitrites supporting urinary tract inflammation/infection
Mid-stream urine (culture and sensitivity):Identifies causative urinary organisms (for example E. coli, Proteus, Enterobacter) and guides antibiotics
PSA (men >40 years, or any age with suspicious features/family history):Raised PSA may indicate prostate inflammation or malignancy and warrants urological assessment in context
Digital rectal examination:Tender/enlarged prostate in prostatitis; hard irregular nodules raise concern for prostate cancer
STI testing (NAATs; GUM pathway):Detects chlamydia/gonorrhoea and enables partner notification
FBC and coagulation profile:May show haematological disease or coagulopathy contributing to bleeding
U&E, LFTs:Assesses renal/hepatic contributors and treatment safety
Semen microscopy/culture when atypical infection suspected:Can support diagnosis of chronic infection, including TB or schistosomiasis in the right clinical context
Scrotal ultrasound (if testicular symptoms/signs):Identifies epididymo-orchitis, testicular mass, or other structural pathology
Specialist imaging/cystoscopy (urology-led for persistent/recurrent or age >40 with unexplained symptoms):May identify seminal vesicle/ejaculatory duct cysts, calculi, obstruction, or urothelial lesions

Management

Lifestyle Modifications

  • Reassure: isolated haematospermia in men under 40 with normal initial assessment is often benign/self-limiting
  • Safety-net: return urgently for recurrence, persistence, haematuria, constitutional symptoms, testicular change, or worsening pain
  • Sexual health advice and abstain from unprotected sex until STI assessment/treatment completed
  • Address cardiovascular risk and blood pressure control
  • Explain fertility is usually unaffected, except when untreated STI causes reproductive tract damage

Pharmacological Treatment

Lower UTI in men (culture-guided first line in UK practice)

  • Nitrofurantoin modified-release 100 mg twice daily for 7 days
  • Trimethoprim 200 mg twice daily for 7 days (if low resistance risk)

Use local antimicrobial guidance and sensitivities. Nitrofurantoin is generally unsuitable if eGFR <45 mL/min/1.73 m2 (short-course caution may apply at 30-44 in selected cases). Trimethoprim can cause hyperkalaemia, especially with ACE inhibitors/ARBs/spironolactone.

Acute bacterial prostatitis

  • Ciprofloxacin 500 mg twice daily for 14 days then review (often total 28 days if improving)
  • Ofloxacin 200 mg twice daily for 14 days then review

Fluoroquinolones carry MHRA safety warnings (tendon injury, neuropathy, CNS effects); avoid in people with prior serious quinolone adverse reactions and use only when benefits outweigh risks.

Chlamydia-associated urethritis/epididymal involvement (via GUM)

  • Doxycycline 100 mg twice daily for 7 days

Avoid in pregnancy; photosensitivity risk; ensure partner notification and test-of-cure strategy per sexual health protocols.

Gonorrhoea (specialist sexual health treatment)

  • Ceftriaxone 1 g intramuscular single dose

Manage through GUM due to resistance patterns and mandatory contact tracing; check severe beta-lactam allergy history.

Hypertension treatment when contributory

  • Amlodipine 5 mg once daily (typical first-line option in many adults)
  • Ramipril 2.5 mg once daily (when ACE inhibitor indicated)

Tailor to NICE hypertension pathway by age/ethnicity/comorbidity; monitor renal function and potassium with ACE inhibitors.

Surgical / Interventional

  • No procedure needed for most isolated benign episodes
  • Urology-led cystoscopy or MRI/TRUS assessment for persistent/recurrent or unexplained cases
  • Endoscopic treatment of identified ejaculatory duct obstruction/cysts/calculi when symptomatic and persistent
  • Cancer-pathway referral (2-week wait) for suspected prostate, testicular, or urothelial malignancy

Complications

  • Anxiety and psychosexual distress
  • Missed underlying malignancy if red flags are not investigated
  • Persistent/recurrent haematospermia requiring specialist work-up
  • Ascending or chronic genitourinary infection if untreated
  • Subfertility risk in untreated STI-related disease
  • Drug adverse effects (for example fluoroquinolone toxicity, antibiotic-associated diarrhoea/C. difficile, bleeding interactions with anticoagulants)

Prognosis

Overall prognosis is good: most cases are benign and settle spontaneously. In observational data, spontaneous resolution occurred in about 89% with median duration around 1.5 months, though recurrence can occur. Risk of serious pathology rises with age over 40, persistence/recurrence, and accompanying red-flag features.

Sources & References

NICE Guidelines(1)

Test Your Knowledge

6 quiz questions available for this topic

Start Quiz